MedTrace Logo

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2021-10-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.

Conditions

  • Heart Failure, Reduced Ejection Fraction

Interventions

DRUG

sacubitril/valsartan (LCZ696)

sacubitril/valsartan tablet taken orally.

DRUG

enalapril

Enalapril tablet taken orally.

DRUG

matching placebo sacubitril/valsartan (LCZ696)

matching placebo sacubitril/valsartan tablet taken orally

DRUG

matching placebo enalapril

matching placebo enalapril tablet taken orally

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-16
Primary Completion
2018-03-19
Completion
2018-03-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970669 on ClinicalTrials.gov